Pentoxifylline is a prescription medication approved for the treatment of intermittent claudication, the cramping leg pain that strikes during walking when blood flow to the muscles is restricted by peripheral artery disease. It has been on the market since the 1970s, and while its official indication remains narrow, the drug has quietly accumulated a long list of off-label uses that span liver disease, kidney protection, wound healing, and more. Its side effects are generally mild, with nausea and digestive upset being the most common complaints, but understanding both the benefits and limitations of pentoxifylline requires looking well beyond the label.
How Pentoxifylline Works
Pentoxifylline belongs to a class of drugs called non-selective phosphodiesterase inhibitors, but what matters for the person taking it is what that translates to inside the body. The drug makes red blood cells more flexible, so they can squeeze through narrowed or damaged blood vessels more easily. It also reduces the overall thickness of blood and dials down the tendency of platelets to clump together and form clots.1PubMed. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy These changes improve microcirculation, the flow of blood through the smallest vessels where oxygen delivery to tissues actually happens.2American Heart Journal. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients
Beyond its blood-flow effects, pentoxifylline has anti-inflammatory and antifibrotic properties. It reduces levels of tumor necrosis factor-alpha (TNF-α), a signaling molecule that drives inflammation in many disease states. It also appears to interfere with the formation of scar tissue. These secondary properties explain why the drug keeps showing up in research on conditions that have nothing to do with leg pain, from liver fibrosis to radiation-damaged bone.
The FDA-Approved Use for Intermittent Claudication
Intermittent claudication is a hallmark symptom of peripheral artery disease. Fatty deposits narrow the arteries supplying the legs, so during exercise the muscles cannot get enough oxygen-rich blood. The result is a cramping, aching pain that forces you to stop walking. Pentoxifylline was the first oral drug approved specifically for this problem, and the standard dose is 400 mg taken three times daily with meals.
The evidence behind this approval, however, is less clear-cut than you might expect. A Cochrane systematic review examining trials that compared pentoxifylline to placebo found that most studies suggested a possible improvement in how far people could walk before pain started and in total walking distance, but the certainty of that evidence was rated low. The studies varied widely in duration, dose, and the types of patients enrolled, which made it difficult to pool the results meaningfully.3PubMed Central. Pentoxifylline for intermittent claudication In practical terms, the benefit exists but tends to be modest. Walking programs and management of cardiovascular risk factors remain the foundation of treatment.
How It Compares to Cilostazol
Cilostazol is the other oral drug approved for intermittent claudication, and head-to-head comparisons have generally favored it. In one trial, cilostazol-treated patients improved their maximum walking distance by about 107 meters after 24 weeks, while pentoxifylline-treated patients improved by only 64 meters, a gain that was statistically indistinguishable from placebo.4PubMed. A comparison of cilostazol and pentoxifylline for treating intermittent claudication A more recent meta-analysis confirmed that cilostazol provided a significantly greater improvement in maximum walking distance, though the two drugs did not differ significantly in how far patients could walk before pain first appeared.5Journal for Cardiovascular Angiography and Interventions. Comparative Effectiveness of Cilostazol and Pentoxifylline in Peripheral Artery Disease: A Systematic Review and Meta Analysis
This does not make pentoxifylline useless for claudication. Cilostazol is contraindicated in heart failure, so pentoxifylline remains an option for patients who cannot take it. Some patients also tolerate pentoxifylline better; cilostazol causes more headaches, palpitations, and diarrhea. Still, if your doctor starts you on pentoxifylline for leg pain and the improvement feels underwhelming after two to three months, the evidence supports asking about switching.
Severe Alcoholic Hepatitis
One of the most studied off-label uses for pentoxifylline is in severe alcoholic hepatitis, a dangerous liver inflammation that can develop in heavy drinkers. Corticosteroids have long been the primary treatment, but pentoxifylline emerged as an alternative after a landmark trial showed it cut mortality significantly, largely by reducing a feared complication called hepatorenal syndrome. In that trial, half of pentoxifylline-treated patients who died had renal failure as the cause, compared to more than nine in ten among controls. The drug reduced the development of new hepatorenal syndrome by about 65% and deaths from it by about 70%.6Gastroenterology. Pentoxifylline in severe alcoholic hepatitis and reduction of hepatorenal syndrome
A later systematic review pooling data from multiple trials confirmed a reduced incidence of fatal hepatorenal syndrome with pentoxifylline compared to placebo.7PubMed. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis Some research has also explored combining pentoxifylline with corticosteroids; this dual therapy appeared to lower rates of hepatorenal syndrome and infection risk compared to corticosteroids alone.8Journal of Clinical Gastroenterology. Treatment of Severe Alcoholic Hepatitis With Corticosteroid, Pentoxifylline, or Dual Therapy The role of pentoxifylline in this space remains debated, and practice varies between hospitals, but its kidney-protective effect in the setting of severe liver disease is one of the more compelling findings in the drug’s portfolio.
A separate retrospective study following patients with compensated cirrhosis over roughly two decades found that those on long-term pentoxifylline treatment had notably delayed progression to decompensated cirrhosis and long overall survival times, suggesting the drug’s anti-inflammatory and antifibrotic properties may have broader relevance in chronic liver disease.9PubMed Central. Prolonged use of pentoxifylline increases the life expectancy of patients with compensated cirrhosis: A 20‑year retrospective study
Diabetic Kidney Disease
Pentoxifylline has attracted substantial interest as an add-on treatment for diabetic kidney disease, specifically for patients already taking standard blood-pressure drugs that protect the kidneys. In a well-designed trial called PREDIAN, adding pentoxifylline to these standard medications slowed the decline in kidney function considerably. Kidney filtration rate fell by only about 2 ml/min over the study period in the pentoxifylline group, compared to roughly 6.5 ml/min in the control group. Protein spillage into the urine, a marker of kidney damage, also dropped.10PubMed Central. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial
A separate multicenter trial showed that pentoxifylline reduced protein in the urine by roughly 20% at six months compared to placebo.11PubMed Central. Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study A review of the evidence concluded that pentoxifylline shows significant antiproteinuric effects and slows the loss of kidney function, though definitive evidence on hard renal outcomes like dialysis or transplant is still lacking.12PubMed Central. Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons For now, pentoxifylline sits in a promising but not-yet-guideline-endorsed position for kidney protection.
Venous Leg Ulcers
Venous leg ulcers are chronic wounds on the lower legs caused by poor blood return through the veins. Compression bandaging is the cornerstone treatment, but healing can be frustratingly slow. Pentoxifylline, added on top of compression therapy, has shown real benefit. A Cochrane review found that pentoxifylline plus compression was significantly more effective than compression alone, and the drug may even help when compression is not feasible.13PubMed Central. Pentoxifylline for treating venous leg ulcers
A randomized trial testing different doses found that ulcers healed faster with pentoxifylline, and a higher dose of 800 mg three times daily outperformed the standard 400 mg dose. The median time to complete healing was about 71 days for the higher dose compared to 100 days for placebo, a meaningful acceleration for wounds that can linger for months or years.14PubMed. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial This is one area where pentoxifylline’s evidence base is genuinely strong, and wound-care specialists prescribe it with reasonable confidence.
Peyronie’s Disease
Peyronie’s disease involves the buildup of fibrous plaque inside the penis, leading to curvature, pain, and sometimes calcification. Because pentoxifylline has antifibrotic properties, it has been trialed in this condition with encouraging results. A double-blind placebo-controlled study found that pentoxifylline significantly reduced penile curvature and plaque volume in early-stage disease compared to placebo.15PubMed. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie’s disease
Another study found that over 90% of men treated with pentoxifylline showed improvement or stabilization in plaque calcification, compared to fewer than half of untreated men. Those taking the drug were also far less likely to report subjective worsening of their condition.16PubMed Central. Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease When combined with other conservative measures like penile traction and colchicine, pentoxifylline was associated with significant decreases in both curvature and plaque size over six months.17Sexual Medicine. Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie’s Disease The drug is not a cure, but for men in the early or active phase of the disease who want to try a non-surgical approach, it is one of the more commonly prescribed oral options.
Radiation-Related Bone Damage
Osteoradionecrosis is a serious complication of radiation therapy in which bone, most often in the jaw, loses its blood supply and begins to die. It is notoriously difficult to treat once established. A combination of pentoxifylline and vitamin E (tocopherol), sometimes abbreviated PENTO, has gained traction as a non-surgical treatment option. A systematic review found that across all included studies, some proportion of patients achieved complete mucosal coverage with no exposed bone after PENTO treatment, ranging from about 17% to 100% depending on the study. Disease stabilization or improvement was common, while frank progression occurred in a minority of patients.18PubMed Central. Pentoxifylline and tocopherol for the treatment of osteoradionecrosis of the jaws. A systematic review The combination appeared most effective for mild to moderate cases, with advanced disease responding less well. This pairing of pentoxifylline with vitamin E exploits the drug’s ability to improve microcirculation in radiation-damaged tissue while vitamin E contributes antioxidant protection.
Vascular Dementia
Given that pentoxifylline improves blood flow through small vessels, researchers have explored whether it could slow cognitive decline caused by vascular damage in the brain. A systematic review of four trials found a trend toward improved cognitive function in patients treated with pentoxifylline, and when studies used stricter definitions for vascular dementia, statistically significant differences emerged between the pentoxifylline and placebo groups.19PubMed. The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review One of those individual trials showed that among patients who had imaging-confirmed evidence of stroke, pentoxifylline significantly slowed deterioration on cognitive testing.20PubMed. Pentoxifylline in cerebrovascular dementia
These results are intriguing but dated; most of these trials were conducted in the 1990s and were relatively small. The evidence was never strong enough to establish pentoxifylline as a standard treatment for dementia, and newer drugs and approaches have since taken center stage. Still, the findings are a useful reminder of how broadly the drug’s vascular and anti-inflammatory effects can ripple through the body.
Necrobiosis Lipoidica
Necrobiosis lipoidica is a rare skin condition, often seen in people with diabetes, that causes waxy, yellowish-brown patches that can break down into painful ulcers. It is notoriously resistant to standard treatments. Case reports and small series have documented successful treatment with pentoxifylline, including cases where ulcerated lesions healed completely within weeks of starting the drug.21Clinical and Experimental Dermatology. Ulcerating necrobiosis lipoidica effectively treated with pentoxifylline A later case series reported that early-stage disease could be completely reversible with pentoxifylline treatment, in addition to confirming the drug’s usefulness for ulcerative forms of the condition.22PubMed. Pentoxifylline: An effective therapy for necrobiosis lipoidica
Interest in this application has recently been formalized. A small clinical trial tested a deuterated analog of pentoxifylline, a chemically modified version designed to last longer in the body, specifically for necrobiosis lipoidica. Half of participants achieved clear or near-clear skin, and both patients with ulcerated lesions achieved complete ulcer closure.23JAMA Dermatology. Deuterated Pentoxifylline Analog in the Treatment of Necrobiosis Lipoidica: A Nonrandomized Clinical Trial The evidence remains thin compared to the drug’s more established uses, but for a condition with few good options, pentoxifylline is a reasonable trial.
Side Effects and Tolerability
Pentoxifylline’s side-effect profile is one of its advantages. The most common complaints are gastrointestinal: nausea, upset stomach, bloating, and occasionally diarrhea or vomiting. Taking the drug with food helps, and many people find the symptoms settle after the first few weeks. In a study of breast cancer patients taking pentoxifylline alongside vitamin E after radiation, nausea was the most frequently reported reason for modifying or stopping the drug.24Advances in Radiation Oncology. Pentoxifylline and vitamin E drug compliance after adjuvant breast radiation therapy
Other reported side effects include dizziness, headache, and flushing. These tend to be dose-related, meaning they are more likely at higher doses and often manageable by temporarily reducing the dose. Serious adverse events are uncommon. In the large head-to-head trial comparing pentoxifylline and cilostazol, rates of serious events were similar across all groups including placebo.4PubMed. A comparison of cilostazol and pentoxifylline for treating intermittent claudication
Contraindications, Bleeding Risk, and Drug Interactions
Pentoxifylline is contraindicated in people with recent bleeding in the brain or the retina, because the drug’s effects on blood flow and platelet activity could worsen such events.25Nature. The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment People with known hypersensitivity to pentoxifylline or other methylxanthines, a chemical family that includes caffeine and theophylline, should also avoid it.
Because the drug reduces platelet clumping, the question of interaction with blood thinners comes up regularly. Animal data found no significant change in the anticoagulant effect of warfarin when pentoxifylline was added.26PubMed. Lack of pharmacodynamic interaction between pentoxifylline and warfarin in the rat In clinical practice, however, most physicians still recommend monitoring clotting times more closely if you start pentoxifylline while on warfarin or similar anticoagulants. The drug can also lower blood pressure slightly, which is worth knowing if you are on antihypertensive medications.
Dosing and What Happens in Kidney Disease
The standard dose of pentoxifylline for intermittent claudication is 400 mg three times a day, taken with meals. For off-label uses, doses vary. Venous leg ulcer research has tested doses as high as 800 mg three times daily with better results, while Peyronie’s disease studies have sometimes used 400 mg twice daily.
Pentoxifylline is extensively metabolized in the liver, and its breakdown products are cleared through the kidneys. The parent drug itself does not accumulate significantly in people with kidney problems, but some of its metabolites do. Research on multiple-dose pharmacokinetics in kidney impairment has suggested reducing to 400 mg twice daily for moderate kidney disease and as low as 200 to 400 mg once daily for severe impairment, along with close monitoring.27PubMed. Multiple-dose pharmacokinetics of pentoxifylline and its metabolites during renal insufficiency This is particularly relevant given the growing interest in using pentoxifylline for diabetic kidney disease, where the very patients who might benefit most are also the ones who need dose adjustments.
Food increases the amount of drug absorbed into the bloodstream, which is why the standard advice is to take it with meals. Sustained-release tablet formulations are the most commonly prescribed version and tend to provide more stable drug levels than older formulations.28Frontiers in Pharmacology. Evaluation of pharmacokinetics and relative bioavailability of pentoxifylline and its metabolite in beagle dogs following different formulations If nausea is a problem, splitting the dose or taking it after a full meal rather than a snack can sometimes help.
Why a Decades-Old Drug Keeps Attracting New Research
Pentoxifylline occupies an unusual position in medicine. Its approved indication is supported by evidence that, honestly, is not overwhelming, and a competing drug performs better in head-to-head comparisons. Yet the drug keeps generating fresh studies across wildly different conditions. The reason is its mechanism. A drug that simultaneously improves microcirculation, damps down inflammation, and slows scar formation has obvious theoretical appeal in any condition driven by those processes. And because pentoxifylline has been around for decades, its safety profile is well characterized, the pill is inexpensive, and it is available generically worldwide. That makes it an attractive candidate for repurposing in conditions where treatment options are limited or prohibitively expensive. Whether it is protecting kidneys, closing ulcers, softening Peyronie’s plaques, or coaxing damaged jawbone to heal, the thread connecting all of these uses is the same cluster of vascular and anti-inflammatory effects acting on different tissues. For a drug that seldom makes headlines, pentoxifylline has a remarkably broad footprint in the medical literature.